Updating the BAD’s guidelines for biologic therapy for psoriasis 2017

The BAD’s guidelines for biologic therapy for psoriasis was published in the September 2017 edition of the BJD. The guideline evaluated the biologic agents etanercept, infliximab, adalimumab, ustekinumab, secukinumab and ixekizumab.

The BAD’s guideline development methodology\(^1\) states that all guidelines will be updated every 5 years as standard with the option to review the literature after 2 years post-publication. However, the fast-moving nature of this therapeutic area warrants at least a more frequent review of the literature, with potential changes required to officially published recommendations.

The guideline development group (GDG) had agreed that an annual literature review (of newly published materials that meet the guideline’s original systematic review protocols) should be undertaken. The first review will commence in September 2018.

The collated evidence review will be considered by the GDG lead and Therapy & Guidelines sub-committee in the context of the existing recommendations. Where evidence is considered likely to require an update of the recommendations, a formal GDG meeting will be held to review and revise the recommendations, in line with the BAD’s GRADE-based guideline methodology.\(^1\)

BAD Clinical Standards Unit